FDA CDC News
FDA Simplifies Use of Bivalent mRNA COVID-19 Vaccines for All Doses Administered to Individuals 6 Months and Older
Last Updated on April 18, 2023 by Daily News Staff
The U.S. Food and Drug Administration (FDA) has amended the emergency use authorizations (EUAs) of the Moderna and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals.
This includes authorizing the current bivalent vaccines (original and omicron BA.4/BA.5 strains) to be used for all doses administered to individuals 6 months of age and older, including for an additional dose or doses for certain populations.
The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.
Source FDA
https://stmdailynews.com/category/lifestyle/
